Enclosed herewith Announcement pertaining to update on USFDA.
REGULATORY
▲ Positive Development
LOW RISK
📅 Filed on BSE: 22 Apr 2026, 11:48 AM IST · BSE ID: 170b6a77-d345-4cbb-9ba8-1cd3341cd174
View Original BSE Filing (PDF)
💡
In Simple Terms
The US drug regulator inspected the company's drug factory and found one minor issue, which the company fixed. The inspection was successful.
🤖 AI Summary
- USFDA inspection completed at Lote, Maharashtra facility, 2–6 February 2026
- Form 483 issued with one (1) minor observation — no significant deficiencies noted
- Company addressed observation; received EIR rating Voluntary Action Indicated (VAI)
- Confirms full compliance with current Good Manufacturing Practice (cGMP) requirements
🔢 Key Numbers — exact figures from BSE filing, not rounded
Form 483 observations
1 (one minor observation)
USFDA inspection period
2 February 2026 to 6 February 2026
EIR classification
Voluntary Action Indicated (VAI)
🏢 How This Affects the Company
Successful USFDA inspection with minor observation resolution maintains regulatory eligibility for US market operations and strengthens compliance posture for pharmaceutical manufacturing and export.
No operational disruption indicated. One minor observation has been addressed. Manufacturing facility remains operational under cGMP standards.
Reduces regulatory risk by confirming USFDA inspection completion without major findings. VAI classification indicates no warning letter or import detention risk.
👥 What This Means For Shareholders
✅
Action Required
No action required. Filing is informational disclosure under Regulation 30.
👤
Who Is Affected
All shareholders holding Supriya Lifescience shares. USFDA compliance affects regulatory risk profile and US market export eligibility for the entire company.
🔍
Management Signal
Management demonstrates proactive regulatory compliance and swift remediation capability, signaling operational discipline and commitment to cGMP standards.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Verify no follow-up USFDA inspection notice within 180 days of EIR issuance
Monitor for any product import delays or FDA detention notices in Q2 FY27
Track next USFDA routine inspection scheduling — typically 2–3 years post-inspection
LOW RISK
VAI classification indicates no warning letter, import detention, or major deficiency. One minor observation addressed reduces regulatory risk significantly.
💡 Investor Takeaway
USFDA inspection at Supriya Lifescience's Lote facility (2–6 February 2026) concluded with one minor Form 483 observation. Company addressed it; received Establishment Inspection Report with Voluntary Action Indicated (VAI) status. No warning letter or import detention risk.
⚖️ Strengths & Concerns
✅ Positives
- Minor observation only (1 of 483) indicates strong baseline compliance with cGMP standards across facility.
- Proactive remediation completed before EIR issuance; VAI status avoids warning letter or import restrictions.